
# **POWER OF EMPATHY** TRUTH OF SCIENCE

## CORPORATE PRESENTATION JUNE 2024

## **Business Highlights**




- Founded in 2007; profitable from the second year of operations; sustained track record of industry-leading profitability and cash generation
- Youngest among India's Top-20 domestic branded formulation pharmacos
- Chronic and Sub-Chronic therapies > 80% of revenue
- Focused portfolio with Top 25 Mother Brands accounting for ~70% of revenue
- 18 out of Top-25 mother brands are ranked among the Top-5 in respective segments with 6 brands having more than Rs 100 cr revenue
- High prescription ranks with super-specialists and highend consulting physicians
- Fully integrated business model; ~60% of products sold are manufactured in-house
- Pan-India sales and distribution presence




## **Latest Financial Highlights**









#### Industry-Leading Margins and Cash Generation


- Average Gross Margin (FY18 FY24) = 82%
- Average EBITDA margin (FY18 FY24) = 35%
- Average Operating Cashflow to EBITDA ratio (FY18 –

FY24) = **75%** 

Dividend CAGR of 37% from FY20 to FY23

## **Inorganic Strategy Curated to Gain Access to Attractive Therapies**






Total investment of INR 3,511 cr. in acquisitions in the last 24 months

- INR 1,265 crore in FY23
- INR 2,246 crore during Nov '23 Apr '24

## **Significant Diversification of Therapy Mix in the last two years**





• Emerging Therapies (Derma, Insulins, WHC, CNS, Onco, Nephro) now account for ~ 40%

## **R&D Pipeline – Focused on "First In Market" Combinations and Drugs**



Candidates/ Therapy	Development Status	Commercialisation	
2 FDCs in Oral Anti-diabetes	Approved by DCGI	Q3 of FY24	
2 FDCs in Cardiovascular Disease	Clinical Trials	Q1 of FY25	Launched in Q3:
4 FDCs in Diabetes Disease	Clinical Trials (BE)	Q2 of FY25	• Gliclazide-
1 FDC in Diabetes Disease	Clinical Trials	Q3 of FY25	Dapagliflozin
1 FDC CKD related complication	Clinical Trials	Q4 of FY25	<ul> <li>Gliclazide- Sitagliptin</li> </ul>
<ul><li>4 FDCs in CKD Gastro-intestinal</li><li>2 FDCs in Gynecology</li><li>1 FDC in Cardiovascular Disease</li></ul>	Development	FY25	Active pipeline of
<ul> <li>2 New Drugs* in Gastro-intestinal</li> <li>2 New Drugs* in Neurology</li> <li>1 New Drug* in CVD Disease</li> <li>1 New Drug* in Oncology</li> <li>1 New Drug* in CKD</li> <li>1 New Drug* in Ortho</li> <li>1 New Drug* in Pain Management</li> </ul>	Development	FY25	26 products <ul> <li>FDCs #17</li> <li>New Drugs* #9</li> </ul>

\* These drugs are commercially approved in the US; we are developing these for the Indian market

## WHO-GMP approved Manufacturing – Geared up for the Future

## Eris

#### Guwahati Site



- Greenfield unit commissioned in 2016-17
- Capability to manufacture Oral Solids, Softgels and Sachets;
- 1 Lakh sq ft built-up area
- WHO-GMP approved

#### 250+ Products manufactured

40% of FY24 revenues from products manufactured at Guwahati site

Installed Capacity						
Prescription Produ	ucts	Supplements and	Nutraceuticals			
Products	Capacity (mn units pa)*	Products	Capacity (mn units pa)*			
Tablets	1,440	Tablets	25			
Capsules	150	Capsules	25			
Sachets	2.4	·				
Soft Gel Tablets	216	Sachets	1.2			

\*Installed capacity based on two shifts per day | \*For the year ended 31st Mar'24

## Gujarat Site



#### Greenfield Unit commissioned in March 2023; physical footprint 10x of Guwahati unit

- 18% of revenues from products manufactured at Gujarat in FY 24
- 140+ products manufactured

#### 140+ Products manufactured

18% of FY24 revenues from products manufactured at Gujarat site

#### **Installed Capacity**

#### **Prescription Products**

Products	Capacity (mn units pa)*
Tablets	2,160
Capsule	240
Oral Liquid	18
Injectable	36
Ointment	84

## Swiss Parenterals – Sterile Injectables and Emerging Market Exports

•	Platform for an India Sterile Injectables Play	With a large product portfolio and globally accredited manufacturing capabilities, Swiss provides the ideal platform for Eris to launch an India-focused Sterile Injectables business alongside Biocon's Critical Care portfolio	
•	Manufacturing with marquee regulatory accreditations	Swiss manufactures the widest range of SVPs in its two manufacturing units in Gujarat; these are accredited by ~ 50+ regulatory agencies worldwide including the EU-GMP, Brazilian Anvisa, Mexican Cofepris and Australian TGA	
•	IP-Driven Business Robust product pipeline	<ul> <li>Swiss' product range comprises ~ 1000+ active dossiers across 190+ molecules</li> <li>Growth pipeline - another 1000+ dossiers across existing and 40+ new molecules</li> </ul>	
•	Exports to Emerging Markets	Swiss is a leading exporter of SVPs to 80+ RoW markets in Africa, Asia-Pac, Middle East & LatAm; we propose to leverage the Swiss distribution channel to kickstart the export of oral solid dose from our Gujarat facility	UNIT II
•	Product Development Capability	15-member R&D team with significant sterile development capability including liposomal, microsphere, oil-based and depot injections	
•	Manufacturing Infrastructure	Unit I – General - Liquid Vials & Ampoules, Lyophilised Vials, Pre-filled Syringes, General Dry Powder injections, Inhalation Anaesthetics, Sterile Eye/ Ear Drops, Sterile Eye Ointments Unit II – Three dedicated blocks for Penicillins, Cephalosporins, Carbapenems	


## **Top-20 Power Brands Portfolio Contribute ~ 65% of Revenue**



	Our Top 20 Mother Brands contribute ~ 65% of our rev	/enue	Successfully Leveraged Patent Expiration Opportunities
	<u>MAT Mar'24 Sales (₹ Cr)</u>	<u>Market share</u>	
GlimiSavo	e 315	6%	Zomelis Rank #1 among BGx
Erite	174	4%	
ReMerve	<b>e</b> 160	7%	
Insuger	144	11%	
Zomelis	105	7%	<b>GUXI</b> Rank #4 among BGx
Basalog	99	14%	
Tayo	87	4%	
Cyblex	<b>6</b> 83	<b>10%</b>	
Gluxi	t 77	5%	
Remylin	<b>i</b> 73	5%	<b>Layo</b> Rank #4 among BGx
LNBLOC	72	9%	<b>J</b>
Olmin	<i>1</i> 69	9%	
CANMAL	67	24%	
Cosvate	63	8%	Lindres Rank #1 among BGx
Crevast	59	2%	
Tendia	56	7%	
<b>Ator</b> Save	e <u>51</u>	3%	
Rabonik	۲ <u>41</u>	2%	
GÎNKOCER	R - <u>39</u>	35%	Rank #5 among BGx
i 🐥 PSORID™	37	42%	

## **Strong Position in the ~ INR 14,000 Crore Oral Anti-Diabetes Market**





ris has built a full-service presence in Oral Anti-Diabetes therapy with high market ranks in latest generation molecules (DPP4 and SGLT2 inhibitors)						
Sulfonylurea						
GlimiSave	Rank 5					
GlimiSave MV	Rank 2					
Cyblex	Rank 5					
Cyblex <sub>MV</sub>	Rank 1					
OPP4 Inhibitors						
Zomelis	Rank 1 among BGx					
Tendia	Rank 3					
Glura	Rank 5 among BGx					
SGLT2 Inhibitors						
Gluxit	Rank 4 among BGx					

Source: AWACS MAT Mar'24 SMSRC MAT Feb 2024 \* In Covered Market \*\* Among Diabetologists & Endocrinologists BGx – Branded Generics

### High Prescription Ranks among Focus Doctor Specialties



**Eris Prescription Ranking\* among Doctor Specialties** 



## **Two Key Pillars of Our Market Engagement**






The core focus of our market engagement is to enable clinicians to **improve clinical outcomes in patients** through timely and precision diagnosis and treatment

Generation of actionable scientific evidence through Indiacentric studies

Patient Care initiatives for precision diagnosis & treatment

2





The study was published in the Public Library of Science (PLOS) journal

## **1b. India-Centric – The India Heart Study**

37.3%

Female



# IHS Methodology

The investigators examined the blood pressure of **18,918** participants with the help of 1,233 doctors

62.7%

Male

across 15 states

over a period of 9 months.



**42%** of the participants were misdiagnosed and were unaware of their actual health status



42% misdiagnosis - 23.7% of the respondents had white-coat hypertension and 18% of the respondents had masked hypertension



Indians have a higher average resting heart rate of **80 beats per minute**, higher than the desired rate of 72 beats per minute.

&

Expert	Speak

White-coat hypertensives get misdiagnosed as hypertensive and put on anti-hypertensives' medication, which increases the risk of hypotension (low blood pressure, less than SBP 90/60 DBP) in such persons.

On the other hand, a **masked hypertensive** may go undiagnosed, running the risk of complications to the heart, kidney, and brain, leading to premature mortality.

- Dr. Willem Verberk, PhD.

#### The study was accepted and published in the

official journal of






European Society of Hypertension

## **1c. Facilitating Evidence-based Scientific Research and Publications**




#### Scientific Research and Publications facilitated by Eris in reputed International and Indian Journals




Clinical relevance of double-arm blood pressure measurement and prevalence of clinically important interarm blood pressure differences in India primary care

Cardiovascular risk factors of airport visitors in India: results from a nation-wide campaign Usefulness of ambulatory blood pressure measurement for hypertension management in India: the India ABPM study

Cardiovascular risk in newly diagnosed type 2 diabetes patients in India




## 2. Patient Care – Driving Precision Diagnosis and Better Disease Management



- Objective Bring cutting-edge healthcare solutions to patients through the involvement of Key Opinion Leaders
- State-of-the-art diagnosis at home, followed by treatment options
- Helped tens of thousands of patients towards healthier lives through initiatives such as ABPM, CGM and Holter
- Present run-rate of interventions
  - ABPM 1,700+ pm.
  - CGM 350+ pm.

### **Pan-India Sales Presence and Distribution Network**





### **Board of Directors**





Amit Bakshi

Chairman and Managing Director

Sujesh Vasudevan

Independent Director



Krishnakumar V

Executive Director & Chief Operating Officer



Inderjeet Singh Negi Executive Director



Kaushal Shah Executive Director



Rajeev Dalal

Independent Director




Prashant Gupta Independent Director



Kalpana Unadkat

Independent Director



 We place significant emphasis on corporate governance, consistently striving to adopt best-in-class governance practices

### We will continue our focus on Lifestyle Diseases, which will require significant attention and care in the years to come



#### Lifestyle Diseases Prevalence in India

#### Abdominal 351 mn Obesity **Medical Research General Obesity** 254 mn ICMR Survey of Indian population above the 315 mn Hypertensive No. of participants = High Cholesterol 213 mn Results published in 136 mn Pre-diabetic Diabetic 101 mn

age of 20

1,13,043

Lancet Journal

#### **Trends in Lifestyle Diseases**

- Significant increase in prevalence of noncommunicable diseases (NCDs) in India; share of heart disease and metabolic disorders projected to expand in the years to come
- India is called the "Diabetes capital of the world" with 100+ mn diagnosed & 136 mn pre-diabetic cases
- The Average onset age for Diabetes in India is 41 years – being preponed by a few years due to use of steroids in **COVID** management
- Hypertension 315 mn diagnosed cases and Hypercholesterolemia – 213 mn diagnosed cases

## **Our Key Growth Drivers For FY 25 to FY 28**





- Growth in Power Our Top-25 brands account for ~ 70% of our branded formulations revenue Brand Portfolio
  - 6 of these brands have revenues of Rs. 100+ crore and we expect another 3 brands to enter the Rs. 100 crore club in FY25
  - 18 of these brands are ranked among the Top-5 in their respective segments
  - We expect continued growth in this portfolio with high margin and strong cash generation

Expansion in Emerging Specialties

- We derive 40% of our branded formulations revenue from seven emerging specialties – Dermatology, Insulins, Women's Health, CNS, Oncology, Critical Care and Nephrology
- We see significant headroom for disruptive growth in all these segments
- New Product Pipeline
- We will continue to leverage patent expiration opportunities in coming years
- 20+ first-in-market combinations/ products coming up for launch through our own R&D pipeline in FY25
- New Business Segments
- India Injectables Our next INR 1,000 cr vertical in 3-4 years with the Biocon and Swiss Parenterals portfolios
- RoW Exports Acceleration of Injectable exports and kick-starting of Oral Solid Dosage exports

INR 5,000 crore revenue in FY28

## **Safe Harbour Statement**



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions and statements, other than those based on historical facts, including, but not limited to, those that are identified by the use of words such as 'anticipates', 'believes', 'estimates', 'expects', 'intends', 'plans', 'predicts', 'projects' and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in the markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in the healthcare sector;
- Changes in the laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in the political conditions in India and in other global economies.

Should one or more of such risks and uncertainties materialise, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

# Eris

## **Eris Lifesciences Ltd.**

CORPORATE OFFICE:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054

CIN: L24232GJ2007PLC049867 Website : <u>www.eris.co.in</u>

IR Contact Kruti Raval kruti@erislifesciences.com



# APPENDIX


## **Business Structure and Holdings**



- Aprica Healthcare Limited
- Earlier known as UTH Healthcare Limited
- Eris M. J. Biopharm Private Limited
- Earlier known as Kinedex Healthcare Private Limited
- Eris Therapeutics Limited
- Eris Oaknet Healthcare Private Limited Earlier known as Oaknet Healthcare Private Limited
- Swiss Parenterals Limited

Eris Healthcare Private Limited Earlier known as Strides Healthcare Private Limited

#### Eris Pharmaceuticals Private Limited



Shareholding pattern is as on 31 March 2024				
NSE Symbol	ERIS			
BSE Ticker	540596			
Market Cap (₹ Cr)	11,472			
Shares Outstanding (Cr)	14			
Industry	Pharmaceuticals			

## **Financial Summary (1/2)**



P&L Summary	FY18	FY19	FY20	FY21	FY22	FY23	FY24
Revenue	856	982	1,074	1,212	1,347	1,685	2,009
Gross Profit	722	828	903	974	1,089	1,333	1,629
Gross Profit Margin (%)	84.3%	84.4%	84.0%	80.3%	80.8%	79.1%	81.1%
Operating EBITDA	322	345	368	431	485	537	675
Operating EBITDA Margin (%)	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%
PBT	312	317	331	394	442	405	431
PBT Margin (%)	36.5%	32.3%	30.9%	32.6%	32.8%	24.0%	21.5%
PAT	295	291	297	355	406	374	397
PAT Margin (%)	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%
EPS	21.39	21.15	21.61	26.16	29.89	28.10	28.82
Dividend (per share)	0	0	2.87	5.50	6.01	7.35	-
Cash Flow Generation							
Operating Cash Flow (OCF)	235	223	271	375	378	292	486
OCF as % of EBITDA	72.9%	64.7%	73.6%	87.2%	78.0%	54.4 % *	72.0%

Source: Consolidated Financial Statements, INR Cr.

\* OCF as % of Ebitda adjusted for Acquisition related one-off items = 75%

## **Financial Summary (2/2)**



	FY18	FY19	FY20	FY21	FY22	FY23	FY24	
Margin (%)	Margin (%)							
Gross Margin	84.3%	84.4%	84.0%	80.3%	80.8%	79.1%	81.1%	
EBITDA Margin	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%	
EBIT Margin	34.6%	31.4%	29.6%	32.0%	31.2%	24.9%	24.5%	
PAT Margin	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	
Return (%)								
RoCE	51%	33%	30%	34%	34%	20%	19% **	
RoE	74%	44%	30%	31%	33%	22%	20%	
Others								
Debt/Equity	0.4	0.2	0.0	0.0	0.0	0.4	1.1	
EPS (₹)	21.39	21.15	21.61	26.16	29.89	28.10	28.82	
Working Capital (in day	s)							
Receivables	28	31	53	42	44	63	77	
Inventory	28	31	24	28	32	28	34	
Payables	39	31	34	31	32	27	49	
Net Working Capital	18	31	43	40	44	65	62	

BS Summary	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Share Capital	14	14	14	14	14	14	14
Reserves	848	1,137	1,283	1,563	1,895	2,182	2,573
Shareholders Fund	861	1,151	1,296	1,576	1,908	2,196	2,586
Borrowed Funds*	377	176	6	4	80	869	2,772
Tangible Assets	53	55	87	78	168	356	505
Intangible Assets	718	707	792	778	753	2,212	3,824
Treasury Investments + Cash & Bank Balances	376	363	145	416	635	95	1,416

Source: Consolidated Financial Statements, INR Cr | \* Borrowed Funds include Financial Leases | RoCE and RoE is excluding treasury investments, cash & cash equivalents | \*\* Based on full-year proforma EBIT of FY24 acquisitions; excludes the impact of M&A related Amortisation

## **Key Brands in Oral Diabetes Care**



	e presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation molecules (DPP4 and SGLT2 inhibitors)
Sulfonylurea	
GlimiSave	rank 5 in the ~5,500 cr Glimepiride and combinations market
Glimisave MV	rank 2 in Glimeperide + Voglibose + Metformin
Cyblex	rank 5 in the ~850 cr Gliclazide and combinations market
Cyblex MV	rank 1 in Gliclazide + Voglibose + Metformin
DPP4 Inhibit	ors
Zomelis	rank 1 among BGx and rank 3 incl innovator brands - in the ~1,500 cr Vildagliptin and combinations market
Tendia	rank 3 in the ~800 cr Teneligliptin and combinations market
Glura	Our newly launched brand in Sitagliptin market
SGLT 2 Inhib	itors
Gluxit	rank 4 among BGx brands and rank 5 including innovator brands in the Dapagliflozin and combinations mkt.

## **Key Brands in Cardiovascular and VMN Therapies**



Strong presence in Anti-Hypertensives: the largest segment of Cardiac Care		
Eritel	rank 5 in the ~4,800 cr Telmisartan and combinations market	
Eritel CH	rank 5 in Telmisartan + Chlorthalidone market	
Eritel LN	rank 2 in Telmisartan + Cilnidipine market	
Olmin	rank 3 in the ~800 cr Olmesartan and combinations market	
Olmin Trio	rank 1 in Olmesartan + Cilnidipine + Chlorthalidone market	
Olmin CH	rank 2 in Olmesartan + Chlorthalidone market	
LNBLOC	rank 2 in the ~800 cr Cilnidipine and combinations market	
LNBeta	rank 1 in Nebivolol + Cilnidipine market	
Zayo	Our brand in Sacubitril + Valsartan, an important product for managing Heart Failure	
VMN: Specialty focus in core molecules		
<b>Re</b> Merve	rank 2 in the ~2,200 cr Methylcobalamin and combinations market	
Tayo	rank 4 in the ~2,200 cr Cholecalciferol and combinations market	
GÎNKOCER	rank 1 in the ~100 cr Ginkgo Biloba + combination market with 35% market share	

## Key Brands in Derma, CNS and Women's Healthcare Therapies



Leading brands in Medical Dermatology		
Cosvate	rank 6 in the ≈800 cr Clobetasol and combinations market 8% market share	
Cosvate-GM	rank 1 Clobetasol + Gentamicin + Miconazole market	
Cosmelite	rank 9 in Melasma market	
Onabet	rank 1 in Sertaconazole and combinations market 65% market share	
Emerging presence in CNS		
Serlift <sup>×</sup>	rank 2 in Sertraline market with 16% market share	
DESVAL	rank 2 in Divalproex market	
Strategic Launches in Women's Healthcare		
Metital	rank 3 in the Rs. 300+ crore Myo-inositol and combinations market 8% market share	
<b>Drolute</b> <sup>®</sup>	Our newly launched brand in the Rs. 900+ crore Dydrogesterone market	
Raricap <sup>i</sup> rcm	Our newly launched brand in Ferric Carboxymaltose market	



# THANK YOU

## **Eris Lifesciences**